ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect

(E-pub Ahead of Print)

Author(s): Shuainan Li, Wenya Ma, Fan Yang, Yan Xu, Binbin Xu, Benzhi Cai*

Journal Name: Current Drug Targets


Become EABM
Become Reviewer
Call for Editor

Abstract:

ACE2 has long been known as an injury protective protein, which can protect against a variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases, as a negative regulator of RAAS, ACE2 is an extremely important protective factor that mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2, which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms. Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and cardiovascular diseases/heart injury.

Keywords: COVID-19, cardiovascular diseases, heart injury, SARS-CoV-2, ACE2, RAAS.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389450122666210319110320
Price: $95

Article Metrics

PDF: 50